News

CrossBridge Bio, Inc., a pre-clinical biotech firm specializing in next-generation antibody-drug conjugates (ADCs), has agreed to be acquired by Eli Lilly and Company in a deal valued…
Read More...

Replimune Group has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application (BLA) seeking approval of RP1 in…
Read More...

Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, marking…
Read More...

AbbVie has announced encouraging late-breaking results from its Phase 2 IMGN853-0420 clinical trial, showcasing the potential of mirvetuximab soravtansine-gynx in treating recurrent…
Read More...

Daiichi Sankyo and Merck & Co. (known as MSD outside the United States and Canada) have announced that the U.S. Food and Drug Administration has accepted and granted Priority Review…
Read More...

Novo Nordisk has announced a strategic partnership with OpenAI aimed at transforming healthcare through advanced artificial intelligence, with a focus on accelerating drug discovery and…
Read More...

Telix Pharmaceuticals Limited has announced that the U.S. Food and Drug Administration has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, an investigational imaging…
Read More...

C4 Therapeutics, Inc. has announced a new collaboration agreement with Roche to advance research in a promising cancer treatment approach known as degrader-antibody conjugates (DACs).…
Read More...

AC Immune SA has strengthened its long-standing partnership with Eli Lilly and Company through an amendment to their 2018 collaboration agreement, advancing efforts to develop novel…
Read More...

Nxera Pharma Co., Ltd. has reached a key development milestone in its ongoing collaboration with Eli Lilly and Company, advancing joint efforts to develop new treatments for diabetes…
Read More...

Sidewinder Therapeutics has raised $137 million in an oversubscribed Series B financing round, signaling strong investor confidence in its next-generation cancer treatment platform…
Read More...

Jeito Capital has successfully closed its second fund, Jeito II, raising $1.2 billion and exceeding its initial target, in a move that underscores growing investor confidence in…
Read More...

RoosterBio, Inc. has entered into an exclusive distribution agreement with MineBio Life Sciences Limited to expand access to advanced cell therapy manufacturing solutions across China,…
Read More...

Gilead Sciences, Inc. has announced a definitive agreement to acquire Tubulis GmbH, a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs). The…
Read More...

Halozyme Therapeutics, Inc. has announced a new global collaboration and licensing agreement with Vertex Pharmaceuticals Incorporated aimed at advancing innovative drug delivery…
Read More...

Sidewinder Therapeutics has announced the successful close of an oversubscribed $137 million Series B financing round, marking a significant milestone for the emerging biopharmaceutical…
Read More...

Shionogi & Co., Ltd. has secured a major U.S. government contract to expand the development and supply of its antibiotic Fetroja, reinforcing efforts to combat drug-resistant…
Read More...

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance the development of next-generation antisense therapeutics targeting multiple…
Read More...

Neurocrine Biosciences, Inc. has entered into a definitive agreement to acquire Soleno Therapeutics, Inc. in an all-cash transaction valued at approximately $2.9 billion, marking a…
Read More...

Apnimed, Inc. has secured a senior secured credit facility of up to $150 million from funds managed by HealthCare Royalty Partners, providing a major financial boost as the company…
Read More...